The present invention refers to a composition for use in the prevention and/or treatment of dysbiosis. It also refers to the use of said composition for preparing a medicament for the prevention and/or treatment of dysbiosis. Furthermore, it refers to a method of preventing and/or treating of dysbiosis in which said composition is administered to a subject in need thereof.

The present invention refers to a composition for use in the prevention and/or treatment of dysbiosis. It also refers to the use of said composition for preparing a medicament for the prevention and/or treatment of dysbiosis. Furthermore, it refers to a method of preventing and/or treating of dysbiosis in which said composition is administered to a subject in need thereof.

The present invention refers to a composition for use in the prevention and/or treatment of dysbiosis. It also refers to the use of said composition for preparing a medicament for the prevention and/or treatment of dysbiosis. Furthermore, it refers to a method of preventing and/or treating of dysbiosis in which said composition is administered to a subject in need thereof.

The present invention relates to extracts from Fraxinus angustifolia samara, processes for providing such extracts, and methods and uses of the extracts obtained. In particular, the present invention relates to the use of such extracts in reversing obesity-related and/or metabolic syndrome-related gut microbiota dysbiosis treatment, treating or preventing hepatic steatosis, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and modulating and/or adjusting gut microbiota.

The present invention relates to extracts from Fraxinus angustifolia samara, processes for providing such extracts, and methods and uses of the extracts obtained. In particular, the present invention relates to the use of such extracts in reversing obesity-related and/or metabolic syndrome-related gut microbiota dysbiosis treatment, treating or preventing hepatic steatosis, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and modulating and/or adjusting gut microbiota.

A composition for reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes a Nrf2 transcription factors that promotes transcription of antioxidant genes.

A composition for reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes a Nrf2 transcription factors that promotes transcription of antioxidant genes.

A composition for reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes a Nrf2 transcription factors that promotes transcription of antioxidant genes.

A Syringa microphylla seed extract includes the following components by weight based on a total weight of the Syringa microphylla seed extract: 0.4944-0.7142 mg/g of echinacoside, 6.624-7.617 mg/g of oleuropein, 0.4276-0.6309 mg/g of verbascoside, 3.927-4.684 mg/g of syringin, and 4.505-5.250 mg/g of forsythiaside B. A method of preparing the Syringa microphylla seed extract is disclosed. A composition for treating antibiotic-resistant infections that includes the Syringa microphylla seed extract is also disclosed.

A Syringa microphylla seed extract includes the following components by weight based on a total weight of the Syringa microphylla seed extract: 0.4944-0.7142 mg/g of echinacoside, 6.624-7.617 mg/g of oleuropein, 0.4276-0.6309 mg/g of verbascoside, 3.927-4.684 mg/g of syringin, and 4.505-5.250 mg/g of forsythiaside B. A method of preparing the Syringa microphylla seed extract is disclosed. A composition for treating antibiotic-resistant infections that includes the Syringa microphylla seed extract is also disclosed.